- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Kristi Rosa
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
Articles
Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients
September 29, 2022
Article
The FDA has approved sodium thiosulfate to protect the hearing of pediatric patients who are at least 1 year old and are receiving cisplatin-based treatments.
Pegfilgrastim Plus Plinabulin May Help Mitigate Neutropenia Risk in Patients With Myeloma
September 03, 2022
Article
Adding plinabulin to prophylactic pegfilgrastim and antibiotics may help prevent nonengraftment–related febrile neutropenia.
FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease
August 26, 2022
Article
Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.
Prognostic Link Between pCR and Survival Outcomes May Be Key to Personalized Medicine Efforts in Early-Stage TNBC
August 21, 2022
Article
At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments.
Oral Elacestrant Receives Priority Review Status for ER+/HER2– Advanced or Metastatic Breast Cancer
August 18, 2022
Article
Elacestrant, an oral selective estrogen receptor degrader, will undergo evaluation by the FDA for patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.
Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCL
June 26, 2022
Article
Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.
FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors
June 23, 2022
Article
The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.
Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma
May 28, 2022
Article
Tisagenlecleucel received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC
May 27, 2022
Article
Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab received FDA approval as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status
FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations
May 25, 2022
Article
Ivosidenib plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring IDH1 mutations.